LSK-9985

N/A

Report date: 2022/08/24 20:00:31
NME

Base Information

Drug NameLSK-9985
Drug Alias NameHCI-1401
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3Tyrosine-protein kinase BTK
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHuntsman Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesElevar Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A